Rebecca Valentin Selected Research

venetoclax

1/2021	BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia.
12/2020	Combining epigenetic therapy with venetoclax overcomes alemtuzumab resistance in T-cell prolymphocytic leukemia. A case report of a 26-year-old man with a prior history of T-cell acute lymphoblastic leukemia and GI-T lymphoma.
10/2018	Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies.
1/2018	The rise of apoptosis: targeting apoptosis in hematologic malignancies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rebecca Valentin Research Topics

Disease

3	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 12/2020 - 01/2018
2	T-Cell Prolymphocytic Leukemia (Leukemia, T Cell, Chronic) 01/2021 - 12/2020
2	Lymphoma (Lymphomas) 12/2020 - 01/2018
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2018
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2018
1	Multiple Myeloma 01/2018
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2018
1	B-Cell Leukemia (Leukemia, B Cell) 01/2018
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2018
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2018
1	Hematologic Neoplasms (Hematological Malignancy) 01/2018

Drug/Important Bio-Agent (IBA)

4	venetoclaxIBA 01/2021 - 01/2018
2	Alemtuzumab (Campath)FDA Link 01/2021 - 12/2020
1	ruxolitinibIBA 01/2021
1	Reactive Oxygen Species (Oxygen Radicals)IBA 12/2020
1	RNA Splicing FactorsIBA 10/2018
1	Proteins (Proteins, Gene)FDA Link 01/2018

Therapy/Procedure

3	Therapeutics 01/2021 - 01/2018
1	Drug Therapy (Chemotherapy) 01/2021